Ground Swell Capital LLC Purchases New Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Ground Swell Capital LLC acquired a new position in shares of Protalix BioTherapeutics, Inc. (NYSE:PLXFree Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 62,234 shares of the company’s stock, valued at approximately $73,000. Ground Swell Capital LLC owned approximately 0.08% of Protalix BioTherapeutics at the end of the most recent quarter.

Separately, Virtu Financial LLC bought a new stake in Protalix BioTherapeutics during the 1st quarter worth approximately $198,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

Protalix BioTherapeutics Stock Performance

Shares of PLX opened at $1.02 on Wednesday. The stock has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $1.17. The company has a market cap of $74.78 million, a price-to-earnings ratio of 25.50 and a beta of 0.70. Protalix BioTherapeutics, Inc. has a 52-week low of $0.82 and a 52-week high of $1.90.

Protalix BioTherapeutics (NYSE:PLXGet Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.05). The company had revenue of $13.47 million for the quarter, compared to analyst estimates of $12.50 million. Protalix BioTherapeutics had a negative return on equity of 45.15% and a negative net margin of 38.62%. During the same quarter last year, the company earned ($0.07) EPS. As a group, research analysts predict that Protalix BioTherapeutics, Inc. will post 0.06 EPS for the current fiscal year.

Protalix BioTherapeutics Company Profile

(Free Report)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

See Also

Want to see what other hedge funds are holding PLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protalix BioTherapeutics, Inc. (NYSE:PLXFree Report).

Institutional Ownership by Quarter for Protalix BioTherapeutics (NYSE:PLX)

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.